Shanghai, China Viva BioInnovator is the famous VC, which was founded in 2014. The company was established in Asia in China. The leading representative office of defined VC is situated in the Shanghai.
The typical startup value when the investment from Viva BioInnovator is 5-10 millions dollars. The fund is generally included in 2-6 deals every year. Considering the real fund results, this VC is 8 percentage points less often commits exit comparing to other organizations. Deals in the range of 1 - 5 millions dollars are the general things for fund. The top activity for fund was in 2017.
The fund has no exact preference in some founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the most successful fund investment fields, there are Therapeutics, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Mebias Discovery, Tabomedex Biosciences, Inc., QurAlis. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
The standard case for the fund is to invest in rounds with 1-2 partakers. Despite the Viva BioInnovator, startups are often financed by MP Healthcare Venture Management, Amgen Ventures, Alexandria Venture Investments. The meaningful sponsors for the fund in investment in the same round are Sprout BioVentures, MP Healthcare Venture Management, Lumira Ventures. In the next rounds fund is usually obtained by Kaitai Capital.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Ali Jiankang | China, Hebei, Shijiazhuang |
| Ashoka | Arlington, United States, Virginia |
| Blacksmith Capital | California, Palo Alto, United States |
| Fame Mount Limited | - |
| Huijun Venture Capital | China, Shanghai |
| IMAGE WORKS | Japan, Kyoto, Kyoto Prefecture |
| Jinhuanan Investment | China, Futian, Guangdong |
| Kingson Capital Partners | Durban, KwaZulu-Natal, South Africa |
| Live Shark Tank | - |
| Novelion Therapeutics | British Columbia, Canada, Vancouver |
| Sanari Capital | Sandston, United States, Virginia |
| Savitr Capital | California, San Francisco, United States |
| Scientific Health Development Partners | Dallas, Texas, United States |
| Seneca Creek Ventures | Boston, Massachusetts, United States |
| Stow Capital | - |
| Ulmus Investment | - |
| Zhongmi Capital | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Deka Biosciences | $20M | 28 Sep 2023 | Washington, District of Columbia, United States | ||
Domain Therapeutics | $46M | 10 May 2022 | France, Grand Est, France | ||
ArrePath | $20M | 03 Mar 2022 | Princeton, New Jersey, United States | ||
HAYA Therapeutics | $5M | 09 Feb 2022 | Lausanne, Vaud, Switzerland | ||
Amberstone Biosciences | $12M | 03 Jan 2022 | Laguna Hills, California, United States | ||
Fuse Biotherapeutics | $9M | 15 Nov 2021 | Los Angeles, California, United States | ||
Deka Biosciences | $20M | 29 Oct 2021 | Washington, District of Columbia, United States | ||
IpiNovyx Bio | $10M | 05 Oct 2021 | New York, New York, United States | ||
Karma Biotechnologies | $2M | 01 Sep 2021 | Los Angeles, California, United States |
– HAYA Therapeutics, SA, a company developing precision medicines that target tissue and cell-specific long non-coding RNAs (lncRNAs), announced the successful closing of its CHF 18 million seed round.
– The financing was led by Broadview Ventures, with participation from Apollo Health Ventures, BERNINA BioInvest, 4See Ventures, Schroder Adveq and Viva BioInnovator.
– Founded and led by a team of experts in lncRNA biology and fibrotic disease, HAYA will use the funds from the financing to advance the discovery and development of innovative organ and cell-selective therapeutics that target lncRNAs to treat and potentially reverse fibrosis and other serious medical conditions related to aging.
– DTx Pharma, Inc. from San Diego raised $100m in Series B financing.
– The round was led by RA Capital Management with participation from new investors Access Biotechnology, Surveyor Capital (a Citadel company), Cormorant Asset Management, Janus Henderson Investors, and Logos Capital and existing investors Friedman Bioventure Fund, Eli Lilly and Company, Viva BioInnovator (Viva Biotech Holdings, 1873.HK), and ExSight Ventures.
– The company intends to use the funds to utilize its FALCON fatty acid motifs to advance assets into clinical development across several therapeutic areas over the next few years.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Deka Biosciences | $20M | 28 Sep 2023 | Washington, District of Columbia, United States | ||
Domain Therapeutics | $46M | 10 May 2022 | France, Grand Est, France | ||
ArrePath | $20M | 03 Mar 2022 | Princeton, New Jersey, United States | ||
HAYA Therapeutics | $5M | 09 Feb 2022 | Lausanne, Vaud, Switzerland | ||
Amberstone Biosciences | $12M | 03 Jan 2022 | Laguna Hills, California, United States | ||
Fuse Biotherapeutics | $9M | 15 Nov 2021 | Los Angeles, California, United States | ||
Deka Biosciences | $20M | 29 Oct 2021 | Washington, District of Columbia, United States | ||
IpiNovyx Bio | $10M | 05 Oct 2021 | New York, New York, United States | ||
Karma Biotechnologies | $2M | 01 Sep 2021 | Los Angeles, California, United States |
